AU2013274965B2 - Methods, reagents and kits for detecting minimal residual disease - Google Patents

Methods, reagents and kits for detecting minimal residual disease Download PDF

Info

Publication number
AU2013274965B2
AU2013274965B2 AU2013274965A AU2013274965A AU2013274965B2 AU 2013274965 B2 AU2013274965 B2 AU 2013274965B2 AU 2013274965 A AU2013274965 A AU 2013274965A AU 2013274965 A AU2013274965 A AU 2013274965A AU 2013274965 B2 AU2013274965 B2 AU 2013274965B2
Authority
AU
Australia
Prior art keywords
panel
antibodies
cells
markers
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013274965A
Other languages
English (en)
Other versions
AU2013274965A1 (en
Inventor
Julia Maria Almeida Parra
Sebastian Bottcher
Juan Alejandro FLORES MONTERO
Anthonie Willem Langerak
Ester Mejstrikova
Paulo Jorge Monteiro Da Silva Lucio
Jose Alberto Orfao De Matos Correia E Vale
Matthias RITGEN
Tomasz Szczepanski
Vincent Henricus Johannes Van Der Velden
Jacobus Johannes Maria Van Dongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus University Medical Center
Original Assignee
Erasmus University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center filed Critical Erasmus University Medical Center
Publication of AU2013274965A1 publication Critical patent/AU2013274965A1/en
Priority to AU2018204429A priority Critical patent/AU2018204429B2/en
Application granted granted Critical
Publication of AU2013274965B2 publication Critical patent/AU2013274965B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2013274965A 2012-06-14 2013-06-14 Methods, reagents and kits for detecting minimal residual disease Active AU2013274965B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018204429A AU2018204429B2 (en) 2012-06-14 2018-06-20 Methods, reagents and kits for detecting minimal residual disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659524P 2012-06-14 2012-06-14
US61/659,524 2012-06-14
PCT/NL2013/050420 WO2013187765A2 (en) 2012-06-14 2013-06-14 Methods, reagents and kits for detecting minimal residual disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018204429A Division AU2018204429B2 (en) 2012-06-14 2018-06-20 Methods, reagents and kits for detecting minimal residual disease

Publications (2)

Publication Number Publication Date
AU2013274965A1 AU2013274965A1 (en) 2015-01-22
AU2013274965B2 true AU2013274965B2 (en) 2018-07-19

Family

ID=48741458

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013274965A Active AU2013274965B2 (en) 2012-06-14 2013-06-14 Methods, reagents and kits for detecting minimal residual disease
AU2018204429A Active AU2018204429B2 (en) 2012-06-14 2018-06-20 Methods, reagents and kits for detecting minimal residual disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018204429A Active AU2018204429B2 (en) 2012-06-14 2018-06-20 Methods, reagents and kits for detecting minimal residual disease

Country Status (9)

Country Link
US (3) US20150160226A1 (https=)
EP (2) EP3064942B1 (https=)
JP (2) JP6262218B2 (https=)
CN (2) CN107422122B (https=)
AU (2) AU2013274965B2 (https=)
CA (2) CA3022975C (https=)
DK (2) DK2861987T3 (https=)
ES (1) ES2660429T3 (https=)
WO (1) WO2013187765A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150160226A1 (en) 2012-06-14 2015-06-11 Erasmus University Medical Center Rotterdam Method, reagents, and kits for detecting minimal residual disease
WO2015160226A1 (ko) * 2014-04-17 2015-10-22 주식회사 건강사랑 레드클로버 및 석류의 복합 추출물을 유효성분으로 포함하는 조성물의 여성 갱년기 개선 용도
CA2993267A1 (en) * 2015-08-07 2017-02-16 Dana-Farber Cancer Institute, Inc. Genetic abnormalities in plasma cell dyscrasias
CN105223360B (zh) * 2015-08-28 2017-03-22 北京大学人民医院 鉴别检测正常浆细胞和克隆性浆细胞的试剂盒及其应用
CN106290812A (zh) * 2016-09-08 2017-01-04 北京海思特临床检验所有限公司 B细胞恶性肿瘤相关抗原表达量检测试剂盒及检测方法
JP7084695B2 (ja) * 2017-03-28 2022-06-15 シスメックス株式会社 試薬選択支援装置、方法、プログラムおよび記録媒体並びに試料測定装置
CN108458964A (zh) * 2017-10-31 2018-08-28 天津协和华美医学诊断技术有限公司 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
CN109655616B (zh) * 2018-12-19 2022-05-06 广州金域医学检验中心有限公司 检测急性髓系白血病细胞的组合试剂及系统
CN109752548B (zh) * 2019-02-01 2022-05-06 广州金域医学检验中心有限公司 评估慢性淋巴细胞白血病预后的组合试剂及系统
CN109884313A (zh) * 2019-02-22 2019-06-14 武汉康圣达医学检验所有限公司 急性b淋巴细胞白血病微小残留的检测试剂盒
US11933783B2 (en) 2020-02-25 2024-03-19 Seema Singhal Liquid biopsy yield enhancement
CN114487422A (zh) * 2020-10-26 2022-05-13 苏州云泰生物医药科技有限公司 用于监测急性b淋巴细胞白血病微小残留病灶的流式细胞术试剂盒及监测方法
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
CN112552407B (zh) * 2021-02-24 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其在检测急性b淋巴细胞白血病中的应用
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
CN113419066B (zh) * 2021-08-23 2021-11-02 信纳克(北京)生化标志物检测医学研究有限责任公司 一步法筛查和/或诊断克隆性疾病的试剂组合物及其应用
CN113777327B (zh) * 2021-09-13 2022-09-02 北京大学人民医院 用于白血病/淋巴瘤免疫分型初筛的抗体组合物及其应用
CN113933511B (zh) * 2021-09-18 2024-03-22 广州金域医学检验中心有限公司 检测急性b淋巴细胞白血病微小残留的抗体组合物及方法
CN115197322B (zh) * 2022-07-21 2024-01-30 江苏省人民医院（南京医科大学第一附属医院） 用于慢性淋巴细胞白血病微小残留病灶检测的抗体组合物及其应用
CN115491423A (zh) * 2022-09-23 2022-12-20 珠海横琴铂华医学检验有限公司 一种用于b细胞淋巴瘤mrd监测的基因组合、试剂盒与应用
CN116087518B (zh) * 2022-11-02 2025-01-07 北京海思特医学检验实验室有限公司 一种mrd检测产品
CN115902216B (zh) * 2022-12-22 2025-03-18 苏州元德维康生物科技有限公司 筛查和/或诊断浆细胞肿瘤的试剂组合物及其应用
CN115856302B (zh) * 2023-03-02 2023-06-02 北京大学人民医院 用于成熟b细胞肿瘤免疫分型的抗体组合物及其应用
WO2025080137A1 (en) 2023-10-12 2025-04-17 Stichting Euroflow Methods, reagents and kits for detecting minimal/measurable disease in chronic lymphocytic leukemia (cll)
BG113932A (bg) 2024-07-19 2026-01-30 Медицински университет – Пловдив Панели и китове от реагенти за измерване на минимална резидуална болест при детска в-клетъчна прекурсорна остра лимфобластна левкемия чрез имунофенотипизация

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2051651B1 (es) 1992-12-10 1995-01-01 Univ Salamanca Procedimiento para la cuantificacion simultanea, en una sola medicion, de los principales tipos de linfocitos humanos y sus subpoblaciones.
NZ528205A (en) * 2001-03-12 2006-09-29 Monogen Inc Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes
CN1646910A (zh) * 2002-04-09 2005-07-27 学校法人东海大学 白血病、前白血病或非白血病性恶性血液疾病的判定方法以及诊断药
US7507548B2 (en) * 2003-03-04 2009-03-24 University Of Salamanca Multidimensional detection of aberrant phenotypes in neoplastic cells to be used to monitor minimal disease levels using flow cytometry measurements
WO2007053189A2 (en) * 2005-06-01 2007-05-10 Northwestern University Compositions and methods for altering immune function
US20080254047A1 (en) * 2007-02-23 2008-10-16 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through CLEC-6
EP2259065A1 (en) * 2009-06-03 2010-12-08 Erasmus University Medical Center Rotterdam Methods, reagents and kits for flow cytometric immunophenotyping
US9677125B2 (en) * 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples
CN102353793B (zh) * 2011-07-07 2014-01-29 山东轻工业学院 白血病细胞内融合蛋白的二元流式液相阵列检测方法
US20150160226A1 (en) 2012-06-14 2015-06-11 Erasmus University Medical Center Rotterdam Method, reagents, and kits for detecting minimal residual disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Braylan, R., et al. 'Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting', 2001, Cytometry, Part A, Vol. 46, pages 23-27. *
Lucio, P., et al. 'Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL', 1999, Leukemia, Vol.13, pages 419-427. *

Also Published As

Publication number Publication date
US20150160226A1 (en) 2015-06-11
CN104471393B (zh) 2017-07-07
US20210177936A1 (en) 2021-06-17
EP3064942A3 (en) 2016-10-19
JP6262218B2 (ja) 2018-01-17
CA2876405C (en) 2020-01-07
EP3064942B1 (en) 2017-12-20
WO2013187765A3 (en) 2014-04-24
CN104471393A (zh) 2015-03-25
AU2013274965A1 (en) 2015-01-22
AU2018204429A1 (en) 2018-07-05
US11571457B2 (en) 2023-02-07
CA3022975A1 (en) 2013-12-19
CN107422122B (zh) 2020-06-26
WO2013187765A2 (en) 2013-12-19
DK3064942T3 (en) 2018-03-05
CA3022975C (en) 2019-10-01
EP3064942A2 (en) 2016-09-07
US20180140664A1 (en) 2018-05-24
JP2015521733A (ja) 2015-07-30
ES2660429T3 (es) 2018-03-22
EP2861987A2 (en) 2015-04-22
DK2861987T3 (en) 2016-07-04
US10874710B2 (en) 2020-12-29
JP6524197B2 (ja) 2019-06-05
JP2018066752A (ja) 2018-04-26
CN107422122A (zh) 2017-12-01
AU2018204429B2 (en) 2020-04-02
EP2861987B1 (en) 2016-04-27
CA2876405A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
US11571457B2 (en) Methods, reagents and kits for detecting minimal residual disease
AU2021203620B2 (en) Methods, reagents and kits for flow cytometric immunophenotyping
Nguyen et al. FCM data analysis on heterogeneous specimens
Porwit The Expanding Diagnostic Role of Flow Cytometry in Bone Marrow Studies of Patients with Lymphomas and Plasma Cell Disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)